# Sintx Technologies, Inc.: financial statements, quarterly

SINT · Nasdaq · CIK 1269026 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sint.md) · [Financials](/companies/sint/financials.md) · [Filings](/companies/sint/filings.md) · [Insiders](/companies/sint/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sint/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [678](/filings/0001493152-24-044728.md) | [902 d](/filings/0001493152-25-010870.md) | [687](/filings/0001641172-25-010496.md) | [859](/filings/0001641172-25-024040.md) | [799](/filings/0001493152-25-021930.md) | [542 d](/filings/0001493152-26-011924.md) | [369](/filings/0001493152-26-023919.md) | [151](/filings/0001493152-26-037116.md) | [208](/filings/0001493152-25-021930.md) | [290 d](/filings/0001493152-26-011924.md) | [380](/filings/0001493152-26-023919.md) | [452](/filings/0001493152-26-037116.md) |
| Cost of revenue | $k | [117](/filings/0001493152-24-044728.md) | [445 d](/filings/0001493152-25-010870.md) | [223](/filings/0001641172-25-010496.md) | [224](/filings/0001641172-25-024040.md) | [210](/filings/0001493152-25-021930.md) | [154 d](/filings/0001493152-26-011924.md) | [246](/filings/0001493152-26-023919.md) | [94.0](/filings/0001493152-26-037116.md) | [115](/filings/0001493152-25-021930.md) | [102 d](/filings/0001493152-26-011924.md) | [236](/filings/0001493152-26-023919.md) | [174](/filings/0001493152-26-037116.md) |
| Gross profit | $k | [561](/filings/0001493152-24-044728.md) | [457 d](/filings/0001493152-25-010870.md) | [464](/filings/0001641172-25-010496.md) | [635](/filings/0001641172-25-024040.md) | [589](/filings/0001493152-25-021930.md) | [388 d](/filings/0001493152-26-011924.md) | [123](/filings/0001493152-26-023919.md) | [57.0](/filings/0001493152-26-037116.md) | [93.0](/filings/0001493152-25-021930.md) | [188 d](/filings/0001493152-26-011924.md) | [144](/filings/0001493152-26-023919.md) | [278](/filings/0001493152-26-037116.md) |
| Research and development | $k | [2,525](/filings/0001493152-24-044728.md) | [1,824 d](/filings/0001493152-25-010870.md) | [2,019](/filings/0001641172-25-010496.md) | [1,677](/filings/0001641172-25-024040.md) | [796](/filings/0001493152-25-021930.md) | [709 d](/filings/0001493152-26-011924.md) | [1,116](/filings/0001493152-26-023919.md) | [1,238](/filings/0001493152-26-037116.md) | [1,264](/filings/0001493152-25-021930.md) | [969 d](/filings/0001493152-26-011924.md) | [364](/filings/0001493152-26-023919.md) | [573](/filings/0001493152-26-037116.md) |
| Operating income | $k | [(3,614)](/filings/0001493152-24-044728.md) | [(2,723) d](/filings/0001493152-25-010870.md) | [(3,197)](/filings/0001641172-25-010496.md) | [(2,710)](/filings/0001641172-25-024040.md) | [(6,408)](/filings/0001493152-25-021930.md) | [(1,732) d](/filings/0001493152-26-011924.md) | [(2,383)](/filings/0001493152-26-023919.md) | [(2,665)](/filings/0001493152-26-037116.md) | [(3,355)](/filings/0001493152-25-021930.md) | [(2,318) d](/filings/0001493152-26-011924.md) | [(3,207)](/filings/0001493152-26-023919.md) | [(2,888)](/filings/0001493152-26-037116.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(3,190)](/filings/0001493152-24-044728.md) | [(2,321) d](/filings/0001493152-25-010870.md) | [(886)](/filings/0001493152-25-021930.md) | [(2,204)](/filings/0001493152-25-021930.md) | [(6,239)](/filings/0001493152-25-021930.md) | [(1,695) d](/filings/0001493152-26-011924.md) | [(2,292)](/filings/0001493152-26-037116.md) | [(2,318)](/filings/0001493152-26-037116.md) | [(3,539)](/filings/0001493152-25-021930.md) | [(2,215) d](/filings/0001493152-26-011924.md) | [(2,821)](/filings/0001493152-26-037116.md) | [(2,706)](/filings/0001493152-26-037116.md) |
| Diluted EPS | $ per share | [(161.21)](/filings/0001493152-24-044728.md) | not reported | [(21.66)](/filings/0001641172-25-010496.md) | [(3.61)](/filings/0001641172-25-024040.md) | [(6.96)](/filings/0001493152-25-021930.md) | not reported | [(1.29)](/filings/0001493152-26-023919.md) | [(0.91)](/filings/0001493152-26-037116.md) | [(3.46)](/filings/0001493152-25-021930.md) | not reported | [(0.70)](/filings/0001493152-26-023919.md) | [(0.75)](/filings/0001493152-26-037116.md) |
| Basic EPS | $ per share | [(151.61)](/filings/0001493152-24-044728.md) | not reported | [(10.26)](/filings/0001641172-25-010496.md) | [(3.49)](/filings/0001641172-25-024040.md) | [(6.96)](/filings/0001493152-25-021930.md) | not reported | [(1.29)](/filings/0001493152-26-023919.md) | [(0.91)](/filings/0001493152-26-037116.md) | [(3.46)](/filings/0001493152-25-021930.md) | not reported | [(0.70)](/filings/0001493152-26-023919.md) | [(0.75)](/filings/0001493152-26-037116.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | period not labelled (2025-02-19) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.3](/filings/0001493152-25-010870.md) | [5.8](/filings/0001493152-24-018961.md) | [4.6](/filings/0001493152-24-031644.md) | [4.8](/filings/0001493152-24-044728.md) | [3.6](/filings/0001493152-26-011924.md) | [0.0](/filings/0001493152-26-037116.md) | [6.5](/filings/0001641172-25-010496.md) | [4.3](/filings/0001641172-25-024040.md) | [6.3](/filings/0001493152-25-021930.md) | [4.1](/filings/0001493152-26-037116.md) | [1.9](/filings/0001493152-26-023919.md) | [3.6](/filings/0001493152-26-037116.md) |
| Current assets | $m | [5.5](/filings/0001493152-25-010870.md) | [7.5](/filings/0001493152-24-018961.md) | [5.9](/filings/0001493152-24-031644.md) | [6.3](/filings/0001493152-24-044728.md) | [4.5](/filings/0001493152-26-011924.md) | not reported | [7.6](/filings/0001641172-25-010496.md) | [5.5](/filings/0001641172-25-024040.md) | [7.4](/filings/0001493152-25-021930.md) | [5.7](/filings/0001493152-26-037116.md) | [4.3](/filings/0001493152-26-023919.md) | [7.0](/filings/0001493152-26-037116.md) |
| Total assets | $m | [15.4](/filings/0001493152-25-010870.md) | [17.6](/filings/0001493152-24-018961.md) | [15.3](/filings/0001493152-24-031644.md) | [11.3](/filings/0001493152-24-044728.md) | [9.4](/filings/0001493152-26-011924.md) | [0.7](/filings/0001493152-26-037116.md) | [11.4](/filings/0001641172-25-010496.md) | [9.2](/filings/0001641172-25-024040.md) | [11.4](/filings/0001493152-25-021930.md) | [9.5](/filings/0001493152-26-037116.md) | [7.8](/filings/0001493152-26-023919.md) | [10.4](/filings/0001493152-26-037116.md) |
| Current liabilities | $m | [2.9](/filings/0001493152-25-010870.md) | [4.1](/filings/0001493152-24-018961.md) | [3.0](/filings/0001493152-24-031644.md) | [2.1](/filings/0001493152-24-044728.md) | [2.0](/filings/0001493152-26-011924.md) | not reported | [2.2](/filings/0001641172-25-010496.md) | [2.2](/filings/0001641172-25-024040.md) | [4.3](/filings/0001493152-25-021930.md) | [3.7](/filings/0001493152-26-037116.md) | [4.2](/filings/0001493152-26-023919.md) | [3.0](/filings/0001493152-26-037116.md) |
| Total liabilities | $m | [6.6](/filings/0001493152-25-010870.md) | [7.6](/filings/0001493152-24-018961.md) | [6.5](/filings/0001493152-24-031644.md) | [5.7](/filings/0001493152-24-044728.md) | [5.5](/filings/0001493152-26-011924.md) | not reported | [5.4](/filings/0001641172-25-010496.md) | [5.2](/filings/0001641172-25-024040.md) | [7.3](/filings/0001493152-25-021930.md) | [6.6](/filings/0001493152-26-037116.md) | [6.9](/filings/0001493152-26-023919.md) | [5.6](/filings/0001493152-26-037116.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [0.0](/filings/0001493152-25-010870.md) | [0.2](/filings/0001493152-24-018961.md) | [0.2](/filings/0001493152-24-031644.md) | [0.1](/filings/0001493152-24-044728.md) | [0.0](/filings/0001493152-26-011924.md) | not reported | [0.1](/filings/0001641172-25-010496.md) | [0.1](/filings/0001641172-25-024040.md) | [0.1](/filings/0001493152-25-021930.md) | [0.0](/filings/0001493152-26-037116.md) | [0.1](/filings/0001493152-26-023919.md) | [0.1](/filings/0001493152-26-037116.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [8.8](/filings/0001493152-26-011924.md) | [9.9](/filings/0001493152-25-021930.md) | [8.8](/filings/0001493152-25-021930.md) | [5.6](/filings/0001493152-25-021930.md) | [3.9](/filings/0001493152-26-037116.md) | not reported | [6.1](/filings/0001493152-26-037116.md) | [4.0](/filings/0001493152-26-037116.md) | [4.1](/filings/0001493152-25-021930.md) | [2.9](/filings/0001493152-26-037116.md) | [0.9](/filings/0001493152-26-037116.md) | [4.8](/filings/0001493152-26-037116.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,916) d](/filings/0001493152-24-044728.md) | [(3,128) d](/filings/0001493152-25-010870.md) | [(2,733)](/filings/0001641172-25-010496.md) | [(2,215) d](/filings/0001641172-25-024040.md) | [(2,570) d](/filings/0001493152-25-021930.md) | [(1,124) d](/filings/0001493152-26-011924.md) | [(1,301)](/filings/0001493152-26-023919.md) | [(2,409) d](/filings/0001493152-26-037116.md) | [(2,517) d](/filings/0001493152-25-021930.md) | [(2,344) d](/filings/0001493152-26-011924.md) | [(2,491)](/filings/0001493152-26-023919.md) | [(2,767) d](/filings/0001493152-26-037116.md) |
| Capital expenditure | $k | [122 d](/filings/0001493152-24-044728.md) | [74.0 d](/filings/0001493152-25-010870.md) | [174](/filings/0001641172-25-010496.md) | [359 d](/filings/0001641172-25-024040.md) | [11.0 d](/filings/0001493152-25-021930.md) | [146 d](/filings/0001493152-26-011924.md) | [59.0](/filings/0001493152-26-023919.md) | [0.0 d](/filings/0001493152-26-037116.md) | [84.0 d](/filings/0001493152-25-021930.md) | [42.0 d](/filings/0001493152-26-011924.md) | [7.0](/filings/0001493152-26-023919.md) | [84.0 d](/filings/0001493152-26-037116.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | [86.0](/filings/0001493152-26-023919.md) | [47.0 d](/filings/0001493152-26-037116.md) | [0.0 d](/filings/0001493152-25-021930.md) | [0.0 d](/filings/0001493152-26-011924.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [251](/filings/0001493152-23-040669.md) | [2,558](/filings/0001493152-24-018961.md) | [22.2](/filings/0001493152-24-031644.md) | [22.0](/filings/0001493152-24-044728.md) | [172](/filings/0001641172-25-010496.md) | [698](/filings/0001641172-25-024040.md) | [897](/filings/0001493152-25-021930.md) | [1,774](/filings/0001493152-26-023919.md) | [2,535](/filings/0001493152-26-037116.md) | [2,964](/filings/0001493152-25-021930.md) | [4,014](/filings/0001493152-26-023919.md) | [4,850](/filings/0001493152-26-037116.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,664,534 at 2026-08-05, from the cover of the [10-Q filed 2026-08-11](/filings/0001493152-26-037116.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.